OVERVIEW

Precision Medicine in Severe Asthma: The Importance of Phenotypes and Endotypes in Patient Evaluation is organized by Medical Communications Media (MCM), Inc..

Release Date: Sep 13, 2019
Credit Expiration Date: Sep 13, 2020

Accreditation:
The University of Cincinnati designates this enduring material activity for a maximum of .50 AMA PRA Category 1 Credit™.
American Board of Internal Medicine Maintenance of Certification (from ABIM):
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .5 MOC points

Description:
Severe asthma affects only 3-6% of the overall population of asthmatics but accounts for nearly half of the annual expenditures among asthma patients. Advances in the understanding of the pathophysiology of severe asthma have led to the identification of specific asthma endotypes and phenotypes that may be used to better tailor therapy in the future. This activity will explore the value of determining patient endotypes and phenotypes and review biomarker testing that can help clinicians appropriately classify severe asthma patients.

Learning Objectives:
Upon completion of this educational activity, the participant should be able to:
• Identify the characteristics of uncontrolled, difficult-to-treat, and severe asthma.
• Describe how the pathophysiology of asthma produces distinct disease phenotypes/endotypes for the characterization of severe asthma.
• Summarize clinical, laboratory, and other diagnostic findings that are consistent with each phenotype/endotype of severe asthma to improve treatment selection and asthma control.

Additional details will be posted as soon as information is available.